

1. Jordan J. McGing, Postdoctoral Researcher, Sir Peter Mansfield Imaging Centre, University of Nottingham.
2. Sébastien Serres, Assistant Professor of Metabolic Biochemistry, Faculty of Medicine and Health Sciences, University of Nottingham.
3. Rosemary Nicholas, Research Fellow, Sir Peter Mansfield Imaging Centre, University of Nottingham.
4. Ayushman Gupta, Clinical Fellow, Faculty of Medicine and Health Sciences, University of Nottingham.
5. Shellie J. Radford, Senior Research Fellow in Gastroenterology, Faculty of Medicine and Health Sciences, University of Nottingham; NIHR Nottingham Biomedical Research Centre, Nottingham.
6. Aline V. Nixon, Senior Technical Specialist/Research Nurse, David Greenfield Human Physiology Unit, Faculty of Medicine and Health Sciences, University of Nottingham
7. Joanne Mallinson, Human Studies Technician, David Greenfield Human Physiology Unit, Faculty of Medicine and Health Sciences, University of Nottingham.
8. Christopher Bradley, Research Fellow, Sir Peter Mansfield Imaging Centre, University of Nottingham; NIHR Nottingham Biomedical Research Centre, Nottingham.
9. Stephen Bawden, Research Fellow, Sir Peter Mansfield Imaging Centre, University of Nottingham; NIHR Nottingham Biomedical Research Centre, Nottingham. MRI Physics Group, Department of Medical Physics and Clinical Engineering, Singleton Hospital, Swansea.

© The Author(s) 2025. Published by Oxford University Press on behalf of European Crohn's and Colitis Organisation.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<https://creativecommons.org/licenses/by/4.0/>), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.

10. Susan T. Francis, Professor of Physics, Sir Peter Mansfield Imaging Centre, University of Nottingham; NIHR Nottingham Biomedical Research Centre, Nottingham.

11. Paul L. Greenhaff, Professor of Muscle Metabolism, David Greenfield Human Physiology Unit, MRC/Versus Arthritis Centre for Musculoskeletal Ageing Research, NIHR Nottingham Biomedical Research Centre, Faculty of Medicine and Health Sciences, University of Nottingham.

12. Gordon W. Moran, Professor of Gastroenterology, Translational Medical Sciences, School of Medicine, Faculty of Medicine and Health Sciences, University of Nottingham; NIHR Nottingham Biomedical Research Centre, Nottingham.

The work contained within this manuscript was performed between the School of Medicine, the Sir Peter Mansfield Imaging Centre (SPMIC) and the David Greenfield Human Physiology Unit (DGHPU), University of Nottingham, United Kingdom.

Funding and conflicts of interest: This work was supported by the Crohn's and Colitis UK Medical Research Award (M2017/6 to G.W.M) and by the Joan Browne Legacy at the University of Nottingham (PhD scholarship to J.J.M).

Author Disclosures:

1. Jordan J. McGing has nothing to disclose.
2. Sébastien Serres, has nothing to disclose.
3. Rosemary Nicholas, has nothing to disclose.
4. Ayushman Gupta, has nothing to disclose.

5. Shellie J. Radford, has nothing to disclose.
6. Aline V. Nixon, has nothing to disclose.
7. Joanne Mallinson, has nothing to disclose.
8. Christopher Bradley, has nothing to disclose.
9. Stephen Bawden, has nothing to disclose.
10. Susan T. Francis, has nothing to disclose.
11. Paul L. Greenhaff, has nothing to disclose.
12. Gordon W. Moran, has grant income from Astra Zeneca, Pfizer, Jansen and Bristol Myers Squibb. Prof Moran has supported educational events for Pfizer, Abbvie and Bristol Myers Squibb. Prof Moran has provided consultancy services for Pfizer, Abbvie, Alimentiv and Satisfai Health.

Author contributions

1. Jordan J. McGing: Generation, collection, acquisition, analysis and interpretation of data. Drafting and revision of manuscript, approval of final version of manuscript.
2. Sébastien Serres: Conception and design of study, acquisition, analysis and interpretation of data. Drafting and revision of manuscript, approval of final version of manuscript.
3. Rosemary Nicholas: Acquisition and analysis of data. Approval of the final version of the manuscript.
4. Ayushman Gupta: Acquisition and analysis of data. Approval of the final version of the manuscript.
5. Shellie J. Radford: Acquisition of data. Approval of the final version of the manuscript.
6. Aline V. Nixon: Acquisition of data. Approval of the final version of the manuscript.

7. Joanne Mallinson: Acquisition and analysis of data. Approval of the final version of the manuscript.
8. Christopher Bradley: Acquisition of data. Approval of the final version of the manuscript.
9. Stephen Bawden: Acquisition and analysis of data. Approval of the final version of the manuscript.
10. Susan T. Francis: Conception and design of study, acquisition, analysis and interpretation of data. Drafting and revision of the manuscript, approval of the final version of the manuscript.
11. Paul L. Greenhaff: Conception and design of study, interpretation of data. Drafting and revision of manuscript, approval of final version of manuscript.
12. Gordon W. Moran: Conception and design of study, interpretation of data. Drafting and revision of manuscript, approval of final version of manuscript.

Data transparency

The manuscript, data, figures and tables have not been previously published and the manuscript is not under consideration elsewhere. Data, analytical methods and study materials will be made readily available upon discussion with corresponding author.

Abbreviations

Carbon dioxide production (VCO₂), Cerebral blood flow (CBF), Chronic Obstructive Pulmonary disease (COPD), Crohn's Disease (CD), Crohn's and ulcerative colitis questionnaire-32 (CUCQ-32), c-reactive protein (CRP), dual-energy X-ray absorptiometry (DEXA), electrocardiogram (ECG), electronic glomerular filtration rate (GFR), Enzyme-linked immunosorbent assay (ELISA), hospital anxiety and depression scale (HADS) , Healthy volunteer (HV), Inflammatory Bowel Disease (IBD), Magnetic Resonance Imaging (MRI), Magnetic Resonance Spectroscopy (MRS), Minute ventilation (VE),

Multidimensional Fatigue Inventory–20 scale (MFI-20), Montreal cognitive assessment (MoCa), Oxygen extraction fraction (OEF), Oxygen uptake (VO_2), Phosphocreatine (PCr), Post-exercise PCr resynthesis (V_{PCr}), Standard error of the mean (SEM).

Correspondence

Gordon W. Moran, Professor of Gastroenterology, Translational Medical Sciences, School of Medicine, Faculty of Medicine and Health Sciences, University of Nottingham; NIHR Nottingham Biomedical Research Centre, Nottingham.
Gordon.moran@nottingham.ac.uk

Conference presentation

1. McGing, J. J., Nicholas, R., Serres, S., Gupta, A., Radford, S. J., Bradley, C., ... & Moran, G. (2024). P047 Deconditioning in quiescent Crohn's Disease patients with heightened fatigue perception. *Journal of Crohn's and Colitis*, 18(Supplement_1), i309-i311. (ECCO 2024).
2. McGing, J.J., Nicholas, R., Serres, S., Greenhaff, P., Francis, S., & Moran, G. W. (2022, January). ^{31}P MRS and MRI phenotyping of muscle metabolic quality in IBD fatigue. In *JOURNAL OF CROHN'S & COLITIS* (Vol. 16, pp. I171-I172). GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND: OXFORD UNIV PRESS. (ECCO 2022).
3. McGing, J.J., Nicholas, R. Serres, S. Greenhaff, PL. Moran, GW & Francis ST. ^{31}P MRS and MRI phenotyping of muscle metabolic quality in inflammatory bowel disease fatigue. Abstract ISMRM 2021 (Virtual).
4. McGing, J.J . Nicholas, R. Serres, S. Greenhaff, P. & Francis, S. (2020). *Assessment of peripheral muscle deconditioning using ^{31}P -MRS during high intensity ischaemic plantar flexion exercise.* Accepted Abstract, ISMRM, Sydney 2020.

Abstract**Background & Objective**

IBD fatigue aetiology is poorly understood. This study quantified body composition and physical function alongside proton magnetic resonance imaging (^1H MRI) and spectroscopy (^{31}P MRS) measures of organ structure and function in quiescent Crohn's Disease patients (CD) and healthy volunteers (HV), to identify a physiological basis for IBD fatigue.

Methods

Body composition was determined using DEXA and ^1H MRI. Knee extensor isometric strength and isokinetic fatigue were measured using dynamometry. ^1H MRI was used to quantify cardiac output, cerebral blood flow (gmCBF) and brain oxygen extraction fraction (OEF) at rest, and during supine, steady-state exercise and recovery. ^{31}P MRS was used to quantify post-exercise muscle phosphocreatine (PCr) resynthesis.

Results


16 CD and 12 HV (age, sex and BMI matched) were recruited. Fatigue perception was greater (13.9 ± 1 vs 8.3 ± 0.9 , $P=0.001$) and daily step-count was less (5482 ± 684 vs 8168 ± 1123 , $P=0.04$) in CD. During steady-state exercise, gmCBF was less in CD (653 ± 30 vs 823 ± 40 mL/min, $P = 0.003$). Cardiac output and brain OEF were no different. Post-exercise PCr resynthesis was less in CD (17.2 ± 2.0 vs 25.3 ± 2.4 mM min $^{-1}$, $P=0.02$). Body composition, isometric strength and isokinetic fatigueability were no different.

Conclusion

CD self-reported increased fatigue perception and exhibited a slower rate of post-exercise PCr resynthesis compared to HV. This occurred independently of changes in body composition, muscle strength and fatigueability. IBD fatigue may be linked to peripheral muscle deconditioning and lower gmCBF during submaximal exercise.

Accepted Manuscript

Deconditioning in quiescent Crohn's Disease patients with heightened fatigue perception



Accepted Manuscript

Introduction

Heightened fatigue perception is a significant clinical burden for Inflammatory Bowel Disease (IBD) patients, reflected by overt symptoms of tiredness and lethargy during activities of daily living^{1,2}. Consistent with the association between acute inflammation and fatigue³⁻⁵, the prevalence of increased fatigue perception in active IBD has been reported to be as high as 86%⁶. Furthermore, increased fatigue perception commonly persists during disease remission in a large proportion of IBD patients independent of known reversible clinical causes⁷, which impedes the clinical management of fatigue symptoms. Fatigue prevalence (i.e. increased fatigue perception) is reported in 50% of patients with inactive or mild IBD, relative to 22% of healthy non-IBD volunteers⁸, and patients report the burden of fatigue perception to be greater than that of gastrointestinal symptoms⁹. Indeed, fatigue perception impairs quality of life sufficiently to be reported as the commonest reason for work absence in IBD¹⁰. As a result, IBD fatigue has been highlighted as a research priority¹¹.

The aetiology of IBD fatigue is multifactorial¹² and is likely to originate from peripheral and central mechanisms¹³. Premature exercise fatigue in IBD could, for example, be attributable to deficits of central motor and sensory drive and/or reduced motor unit size and recruitment¹⁴. Furthermore, a decline in cardiorespiratory and cardiovascular functional capacity¹⁵, and/or reduced muscle mass and metabolic quality, clinically described as deconditioning, may modulate premature exercise fatigue in IBD. Indeed, the exercise workload and rate of oxygen consumption (VO_2) attained at the point of volitional fatigue during incremental intensity exercise in IBD patients is lower as compared to healthy volunteers (HV)¹⁵⁻¹⁷. Furthermore, the workload at which blood lactate accumulation increases in trajectory during an incremental exercise test in IBD patients has been reported to be lower than that observed in HV¹⁷, with the rate of heart rate recovery following exercise cessation being slower¹⁸. In line with this evidence of physical deconditioning, performance in laboratory-based assessments designed to mimic real world functionality, such as the sit-up and stand test, is also lower in CD relative to HV¹⁹.

This study aimed to quantify body composition, strength and exercise fatigue during repeated muscle contractions in quiescent IBD patients and healthy volunteers to provide robust evidence of increased fatigue perception and premature exercise fatigue in IBD. Furthermore, to better understand its aetiology this study also undertook the most comprehensive metabolic and physiological phenotyping of an IBD cohort to date using multi-organ magnetic resonance imaging (MRI) and ^{31}P MR spectroscopy (MRS) approaches, which included dynamic measurements of metabolic and physiological function during and following in-bore exercise.

Materials and Methods

Volunteer recruitment and screening

This was a single centre observational study recruiting CD participants in remission from Nottingham University Hospitals Trust (NUH). NUH outpatients were screened from clinic lists by a research nurse and 24 eligible patients were contacted. Age, sex and BMI-matched HVs were recruited through advertisement on Nottingham University Hospitals Trust campuses as non-CD controls. The study conformed to the Declaration of Helsinki and was approved by the East Midlands Nottingham 1 Research Ethics Committee (17/EM/0431) and the protocol was registered on ClinicalTrials.gov ([NCT03670693](https://clinicaltrials.gov/ct2/show/study/NCT03670693)).

Primary endpoints comprised measurement of post-exercise skeletal muscle phosphocreatine (PCr) resynthesis rate, cardiac output, and cerebral blood flow and fractional oxygen extraction at rest before, and during and after supine steady-state exercise. Secondary endpoints included supine peak VO_2 , isometric knee-extensor strength, work output during repeated isokinetic knee extension manoeuvres, whole body fat and lean mass, hospital anxiety and depression questionnaire scores, 7-day pedometer data, IBD fatigue scale scores and quality of life measures through the Crohn's and ulcerative colitis questionnaire-32 (CUCQ-32).

Sample size estimations were performed for the primary endpoint of skeletal muscle PCr recovery rate. Post-exercise PCr $\frac{1}{2}$ time is $35s \pm 3$ in HVs vs $45 \pm 4s$ in COPD patients who present with premature exercise fatigue²⁰. Assuming power of 80% and $\alpha=0.05$, 4 subjects in each group would be required to show a difference in ³¹P MRS derived PCr recovery kinetics between a HV group and a fatigueable group with chronic disease.

CD patients (age 16-75 years, BMI $<30\text{kg/m}^2$) in remission were recruited to the study. Inclusion criteria were disease remission, defined as an absence of visible intestinal inflammation on recent ileocolonoscopy or cross-sectional imaging performed within 12 weeks of inclusion to this study, Harvey Bradshaw index <4 , and c-reactive protein (CRP) <5 mg/dl or a faecal calprotectin of <250 $\mu\text{g/g}$. Age and sex-matched HVs with no chronic health conditions were also recruited.

All study participants completed a health screening visit. This included an electrocardiogram (ECG), a full blood count, blood clinical chemistry, liver function estimation, electronic glomerular filtration rate (GFR) estimation, CRP and vitamin D (Nottingham University Hospitals Trust Clinical Biochemistry department). Serum blood was obtained and analysed in-house using enzyme-linked immunosorbent assay (ELISA) kits to measure serum concentration of TNF α , IL-1 and IL-6 (R&D Systems, Abingdon, UK). With regard to fatigue perception, this study recruited all comers irrespective of their fatigue status. Fatigue perception was estimated using the General^{6,21,22} and Physical²³ domains of the Multidimensional Fatigue Inventory–20 scale (MFI-20) and the IBD fatigue scale (CD group only). Both General and Physical fatigue perception scores were used to assess heightened fatigue perception in CD by comparison to HVs using an unpaired *t*-test. Participants completed the hospital anxiety and depression scale (HADS) and Montreal cognitive assessment (MoCa). Exclusion criteria included anaemia, significant

electrolyte, trace element or vitamin deficiency, renal failure, hypokalaemia, arthritis, or arthralgia, significant cardiovascular or respiratory disease, neurological or cognitive impairment, significant physical disability, active or previous prescriptions of corticosteroids (previous 12 weeks), surgical intervention in the last 12 weeks and pregnancy or childbearing in the previous 6 months. We actively excluded study participants who undertook structured exercise training to control for the potential confounding effects of chronic exercise training on study endpoints.

Following screening and entry into the study, continuous physical activity tracking was undertaken for seven days using a pedometer (OMRON HJ-321-E, OMRON Healthcare, Kyoto, Japan).

Physiology laboratory visit: body composition, and muscle and cardiorespiratory function

Body composition was assessed via dual-energy X-ray absorptiometry (DEXA, Lunar prodigy, GE healthcare, Chicago, Illinois) to determine whole body and regional lean and fat masses. Knee extensor isometric strength was measured (Cybex Norm, Rosemont, Illinois, USA) by participants performing three maximum voluntary contractions interspersed with 60s recovery²⁴. Work output was measured during 20 consecutive maximal isokinetic knee extensions at 90°/s angular velocity to maximise recruitment of all motor units.

Following a dedicated familiarisation protocol, volunteers performed an incremental, supine cardiorespiratory exercise test on an air-braked Cardio Step MRI compatible ergometer (Ergospect GmbH, Innsbruck, Austria) to determine minute ventilation (VE), carbon dioxide production (VCO₂), VO₂ and heart rate using an online breath by breath gas analysis system (COSMED Quark CPET, Rome, Italy). Exercise commenced at 50 W and increased by 20 W at 3 min intervals. The test was terminated when volunteers were unable to maintain the required power output, step frequency or when a plateau in VO₂ was observed. Following 90 min rest, a truncated supine exercise test was performed to confirm VO₂ peak. Exercise commenced at 50 W for 3 min followed

by an immediate increase to the peak workload achieved during the previous initial incremental test. The test was continued until volitional exhaustion using an identical termination criterion as the initial test. To enable standardisation of relative exercise intensity across volunteers during within-bore exercise, VO_2 in the final 30 s of each increment was plotted against workload and a linear regression used to calculate the workload corresponding to 50% of supine VO_2 peak.

Arterialised-venous blood gas analysis was performed during the cardiorespiratory exercise test to ensure the subsequent exercise protocol performed within the MRI scanner was undertaken at an intensity below the ventilatory inflection point such that an increase in CO_2 partial pressure during exercise did not confound cerebral vascular responses to exercise. A superficial vein on the dorsal surface of a hand was cannulated in a retrograde manner and placed inside a hand warming unit prior to and during exercise to ensure arterialised-venous blood sampling²⁵. Samples were drawn into heparinised syringes and analysed with a hand held i-STAT blood gas analyser (Abbott Point of Care, USA).

MR visit: brain and cardiac function in response to supine exercise, and muscle composition and phosphocreatine (PCr) resynthesis

Participants undertook two scan sessions on the same day. First, proton MRI measures were collected on a Philips 3T Ingenia wide-bore scanner. A whole body mDIXON scan was collected to quantify lower limb (calf and thigh) muscle volume (adjusted for BSA) and intra-muscular fat fraction (FF) (analysis using semi-automated MATLAB (MathWorks, Natick, MA, USA) script). An MPRAGE brain scan estimated grey matter (GM), white matter (WM) and cerebrospinal fluid (CSF) volume with measures corrected for total intracranial volume (TIV) (Computational Anatomy Toolbox 12 software, Wellcome Department of Cognitive Neurology, UK). Interleaved measures of cardiac output (aortic 2D-QFLOW indexed to body surface area (BSA) to estimate cardiac index (CI)), grey-matter cerebral blood flow (gmCBF) (2D-

QFLOW, analysed using ViewForum, Philips Medical Systems, Netherlands, NL), and brain oxygen extraction fraction (OEF) and grey-matter cerebral metabolic rate of oxygen (gmCMRO) (using T(2)-relaxation-under-spin-tagging (TRUST), analysed using MATLAB)²⁶ were performed at rest, during in-bore steady-state supine stepping exercise and during recovery using a MRI-compatible Cardiostepper ergometer (Ergospect GmbH, Innsbruck, Austria). Supine steady-state isokinetic stepping was performed at a cadence of 70 steps/minute at an intensity of 50% supine VO₂ peak.

Secondly, calf muscle phosphorus (³¹P) MRS data were collected on a Philips 3T Achieva prior to, during, and following ischaemic plantar flexion exercise using an air braked Trispect MRI compatible ergometer (Ergospect GmbH, Innsbruck, Austria). Phosphocreatine (PCr) resynthesis in the medial gastrocnemius muscle following ischaemic in-bore plantar flexion exercise (Trispect, Ergospect GmbH, Austria) during occlusion was measured using ³¹P pulse-acquire MRS with 8 s temporal resolution to estimate in vivo muscle mitochondrial function²⁷ using jMRUI software²⁸.

See the Supplementary Methods for detailed description of MRI and MRS methodologies.

Statistical Analyses

All data were analysed in IBM SPSS Statistics Version 25. Data were checked for normality using a Shapiro-Wilk test. Between group comparisons of single independent variables were analysed by independent *t*-test, or a Mann-Whitney test for non-parametric data.

Between group comparisons of cardiac and brain MRI and ³¹P MRS endpoint measures at rest, and during exercise and recovery was achieved using two-way ANOVA with repeated measures. A Bonferroni correction was applied to all pairwise comparisons. Sphericity was assessed by Mauchly's test of sphericity, if the Greenhouse-Geisser epsilon was ≥ 0.75 , the Huynh-Feldt corrected value was used to correct degrees

of freedom, else the Greenhouse-Geisser correction was used. All data are reported as the mean and standard error of the mean (SEM). Statistical significance was accepted at $P < 0.05$.

Results

Participant demographics

44 volunteers (24 CD, 20 HV) provided written informed consent prior to health screening. Figure 1 details their progression through the study. 23 CD and 19 HV passed health screening, 1 CD failed due to excessive BMI and 1 HV due to history of chronic exercise training. A further 1 CD and 2 HV passed health screening but were lost to follow up prior to study visit 1. Of the remaining 39 volunteers (22 CD, 17 HV), 11 (6 CD, 5 HV) were excluded following visit 1 (2 HV were lost to follow up after equipment failure, 3HV and 2CD failed CPET, 2 CD voluntarily withdrew consent following visit 1, 1 CD relapsed after visit 1 and 1 CD arrived unwell on the day of testing and was subsequently lost to follow up. 28 volunteers completed the study (16 CD, 12 HV).

CD participants were in clinical remission with an HBI score of 2 ± 1 and had a mean disease duration of 14 ± 3 years. Three participants were being prescribed biological therapies and four participants thiopurines at the time of recruitment. Six participants had undergone previous CD-related bowel resections (See supplementary Table 1). HV and CD groups were matched for age (38 ± 4 vs 42 ± 4 years) and BMI (24 ± 0.9 vs 25 ± 1 kg/m²), Table 1.

Calf muscle phosphocreatine resynthesis following ischaemic plantar flexion exercise.

Example data showing ³¹P MRS tracking of PCr and inorganic phosphate during rest, plantar flexion exercise and recovery is shown in Fig. 2A. Baseline calf muscle PCr concentration was no different between the HV and CD group (Table 3.). Ischaemic contraction markedly reduced muscle PCr concentration relative to baseline in both groups ($P < 0.001$, (Table 3.)). The magnitude of end-exercise

PCr depletion was well-matched in HV and CD groups equating to PCr degradation of 81 ± 3 vs $85 \pm 2\%$ relative to resting PCr concentration, (Table 3.)). After reinstatement of limb blood flow following ischaemic exercise, PCr concentration returned to baseline during recovery in both groups (Table 3.). Post-exercise muscle PCr resynthesis was significantly slower in the CD group relative to the HV group ($V_{\text{PCr}} = 17.2 \pm 2.0$ vs 25.3 ± 2.4 mM.min⁻¹, $P = 0.02$, Fig. 2B, Table 3), with data in both groups having a good fit to a mono-exponential recovery function ($r^2 = 0.97 \pm 0.004$ vs 0.98 ± 0.004 , respectively).

Resting calf muscle intracellular pH at baseline did not differ between groups (Table 3.). Ischemic contraction reduced muscle pH at end-exercise ($P < 0.001$), which was not different between groups (Table 3.). Intracellular pH returned to the resting baseline value following recovery in both groups (7.13 ± 0.07 vs 7.19 ± 0.06 , main effect of time: $P < 0.001$, (Table 3.)). The pH kinetics across the exercise task were not different between the HV and CD group (Table 3.).

Cerebral blood flow and oxygenation responses to supine steady-state exercise at 50% VO₂ peak

Grey matter cerebral blood flow was lower in CD than in HV during supine exercise (823 ± 40 vs 653 ± 30 mL/min, $P = 0.003$; group main effect $P = 0.02$, Fig. 3A), and there was also a main effect of time ($P = 0.02$, Fig. 3A). Relative to baseline, gmCBF in the HV group increased significantly on exercise (727 ± 23 vs 823 ± 40 mL/min, $P = 0.027$) before returning to resting levels on recovery (737 ± 29 mL/min). However, this response was blunted in the CD group (Interaction effect $P = 0.06$) where gmCBF did not alter across the task (Fig. 3A).

Brain oxygen extraction fraction (OEF) and gmCMRO₂ was not different between the HV and CD groups, and there was no time effect (Fig. 3B&C).

Baseline CI (as measured from the aortic 2D-QFLOW) Fig. 3D was no different between HV and CD groups (2.84 ± 0.14 vs 2.66 ± 0.21 L/min). There was a main effect of time for CI across the exercise task ($P < 0.001$, Figure. 3D). Relative to baseline measurements, mean CI increased significantly on exercise in both HV and CD groups (4.98 ± 0.27 vs 5.03 ± 0.28 L/min, $P < 0.001$), before decreasing on recovery ($P < 0.001$) and returning to resting baseline levels (2.89 ± 0.16 vs 2.93 ± 0.13 L/min). Similarly, cardiorespiratory function measures of VE, VCO₂, VO₂, and PetCO₂ were no different between the HV and CD group (Supplementary Table 2).

Fatigue perception, psychosomatic scores, and daily step-count

The CD group self-reported greater general fatigue perception relative to the HV group (13.9 ± 1 vs 8.3 ± 0.9 , $P = 0.001$, Table 1). Physical domain fatigue perception scores were not significantly different between the HV and CD groups (Table 1). CD patients reported IBDF Scale scores of 8.7 ± 1.4 (section 1) and 31.5 ± 5.1 (section 2). Both cognitive function and self-reported anxiety and depression symptoms were comparable between groups (Table 1). Daily step-count was less in the CD group compared to the HV group (5482 ± 684 vs 8168 ± 1123 , $P = 0.04$, Table 1).

Serum inflammation measures

In the CD group, all CRP values were < 10 mg/L. We observed no difference in serum TNF-alpha and IL-1 between the HV and CD groups (Table 1). Serum IL-6 concentration was significantly greater in the CD group compared to the HV group (0.80 ± 0.19 vs 0.21 ± 0.07 pg/mL, $P = 0.02$).

Body composition (whole body and regional)

We could not collect a DEXA scan in one HV and two CD patients of the 12 HV and 16 CD patients who completed the study (Figure. 1). DEXA-estimated regional fat and lean masses were no different between the HV and CD group (Figure. 4A). Likewise, both the whole body and appendicular lean mass index, together with bone mineral density, were no different between groups (Table 2). In keeping with this, MRI derived whole leg and calf muscle volume and intra- muscular FF were not different between groups (Table 2).

There was no difference in grey matter and white matter volume between HV and CD participants, but cerebrospinal fluid volume was significantly lower in the CD group than in the HV group (Supplementary Table 3).

Leg strength, work output and exercise fatigue index.

Muscle function data normalized to DEXA measurements of leg lean mass are reported for 11 HV and 14 CD participants (Figure. 4B-C, Table 2). There was no difference in isometric knee extensor strength (Figure. 4B) or isokinetic work output and fatigue index over 20 maximal contractions (Figure. 4C, Table 2) when comparing the CD and HV groups.

Discussion

This study investigated the physiological basis of IBD fatigue by integrating exercise physiology and multiparametric MRI and MRS approaches to achieve unprecedented insight of IBD physiology in quiescent CD who report heightened fatigue perception.

We have shown that the rate of post-exercise muscle PCr resynthesis, a real-time *in vivo* measure of muscle mitochondrial flux, was significantly slower in the quiescent CD that reported increased perception of

fatigue relative to HV. This difference in muscle PCr resynthesis was not accompanied by between group differences in body composition (whole-body and regional) or measures of cardiac index and muscle strength and work output during exercise, and highlights the presence of greater peripheral muscle deconditioning in CD, which is a trait of other chronic conditions where habitual physical activity levels are diminished²⁹. Of possible importance to the heightened perception of fatigue in CD patients was the finding that grey matter CBF during exercise was lower compared to HV but was not associated with group differences in brain OEF and gmCMRO₂.

Peripheral muscle deconditioning

A slowed rate of muscle PCr resynthesis during exercise recovery is a hallmark of muscle deconditioning and is accepted to reflect a decrease in muscle mitochondrial mass and/or reduced mitochondrial function³⁰⁻³². Of note, this effect is present in ageing and chronic diseases with a high prevalence of heightened fatigue perception and premature exercise fatigue. For example, Chronic Obstructive Pulmonary disease (COPD) patients self-report increased fatigue perception³³, have a lower muscle mitochondrial density than HV³⁴ and exhibit slowed post-exercise muscle PCr resynthesis³⁵, which is likely underpinned by their physical inactivity³⁶. Importantly, these deficits in muscle mitochondrial function reflected by slowed post-exercise PCr recovery in ageing and COPD can be reversed by exercise training intervention^{20,30}, when the exercise regimen is of adequate intensity to stimulate mitochondrial adaptation³⁷. This highlights intrinsic mitochondrial function in muscle is not impaired by ageing or chronic disease and points to a positive role for exercise training intervention as a therapeutic approach for premature exercise fatigue in CD^{15,17,38}. In keeping with this, the CD patients in this study were less active than HV, presenting with daily step count of 5482 ± 684 /day, which is consistent with a sedentary lifestyle index of 5000 steps/day or less³⁹ and does not meet recommended daily physical activity guidelines (≥ 7000 steps/day)⁴⁰. In contrast, the HV group daily step count was 8168 ± 1123 steps/day. Physical inactivity is reported across the lifespan in IBD⁴¹⁻⁴³.

This is important as physical activity reduction is associated with reduced mitochondrial function⁴⁴ and other skeletal muscle metabolic deficits. For example, CD patients with blunted muscle hypertrophic signalling were significantly less active relative to patients with normal muscle hypertrophic signalling⁴². Collectively, these data suggest that physical inactivity is a driver of the muscle deconditioning in CD patients with heightened fatigue perception. Whilst the HV group met recommended physical activity guidelines (≥ 7000 steps/day)⁴⁰ their step count remained relatively low. For example, elderly volunteers (71 \pm 4 years) in an ageing study classified as having normal activity levels completed 9983 \pm 2781 steps per day whilst deconditioned, physically impaired elderly participants completed just 6608 \pm 1765 steps/day⁴⁵, which is comparable to the CD cohort in this study. The fact we were able to delineate significant reductions in both step count and muscle mitochondrial function in our CD cohort relative to HV, who themselves demonstrated relatively low levels of recreational physical activity, exemplifies the magnitude of physical inactivity and accompanying deconditioning reported in our CD cohort.

Body composition, muscle strength and fatiguability

Muscle strength has been reported to be less in CD patients than HV and appears to be associated with disease severity^{15,46}. In keeping with some published literature however we found that body composition, muscle strength, and exercise fatigue development were not different between quiescent CD patients and HV^{38,47}. At least part of the divergence in these findings is likely to be explained by the assessment of muscle fatiguability in IBD being undertaken during sustained isometric contraction^{38,46}, which is very much confounded by muscle venous occlusion that occurs during sustained isometric contraction^{48,49}. Muscle fatiguability was assessed in this study by determining total isokinetic work output and fatigue index during 20 repeated maximum voluntary contractions, which is known to recruit quadriceps muscle type I and type II muscle fibres and is not associated with muscle venous occlusion⁵⁰. Whilst exercise fatigue was clearly evident in both CD patients and HV volunteers, there was no evidence of premature

exercise fatiguability in CD. Other reasons for the lack of agreement in the literature regarding physical function in CD is also likely explained by differences in disease severity, level of deconditioning and muscle mass across studies.

Cerebral blood flow

The HV group exhibited an increase in gmCBF from the resting baseline state during exercise, which returned to baseline during recovery. This finding is in keeping with published research demonstrating an increase in cerebral perfusion using transcranial Doppler ultrasound in both young and older volunteers during incremental intensity submaximal exercise⁵¹, which is thought to reflect increased neuronal activity and metabolic flux⁵². However, unlike the HV group, gmCBF did not increase with exercise in the CD group, which was an unexpected novel finding. Brain morphometry measures in the CD group also showed a lower CSF volume than HV, supported by our findings in a larger group⁵³ and a positive association between cerebral blood flow and cerebrospinal fluid flow has been reported in human ageing⁵⁴. Utilising Arterial Spin Labelling MRI, a decrease in CBF below the resting value has been observed in healthy, young athletes following exhaustive intense exercise. Furthermore, the magnitude of this decline was positively associated with exercise time to fatigue and was not accompanied by a compensatory increase in brain OEF⁵⁵. It is plausible to suggest therefore that the failure of gmCBF to increase during exercise in the CD patients in the present study could have been functionally linked to their heightened perception of fatigue, which warrants further investigation. The precise mechanism for the lack of increase in gmCBF during exercise in CD patients in the present study is unclear, particularly given VCO_2 , VO_2 , cardiac index, cerebral OEF and gmCMRO₂ responses to exercise were no different from HV. Nevertheless, quiescent CD patients with heightened fatigue perception have been reported to show greater cerebral blood flow in the resting state (quantified using ASL-MRI) when compared to healthy age and gender matched control

volunteers⁵⁶. The present study could not corroborate this observation, but the authors associated the greater cerebral blood flow in CD with concurrent differences in neurochemical and mental health status.

Study Limitations

This study involved a relatively small but comprehensively phenotyped cohort of quiescent CD patients. This was important because of the limited understanding of the aetiology of persistent fatigue perception reported in quiescent CD, despite the resolution of disease activity^{4,7}. However, it is acknowledged that this study recruited quiescent IBD patients regardless of the severity of self-reported fatigue perception (i.e., all participants were included), which is in line with previous studies³⁸. Fatigue perception scores used to define clinically significant fatigue perception are without standardization and validated cut-off scores², and it is therefore important to consider that not all CD patients in the present study self-reported elevated fatigue burden, which may have influenced study outcomes. Future studies should develop validated cut-offs for fatigue assessment scales used in IBD research to enable better stratification of CD patients based on fatigue perception.

Despite ensuring exercise intensity was well controlled during within-bore exercise in the present study, we cannot dispute that the supine cardiorespiratory exercise testing that is essential for MRI based exercise studies was not as representative of the upright exercise modalities previously employed in CD research^{15,17}.

Finally, it was not possible to establish whether the reduced post-exercise PCr resynthesis in CD in the present study that employed *in vivo* ³¹P MRS and ¹H MRI was attributable to altered intrinsic mitochondrial function or a reduction in mitochondrial mass compared to HV. However, the latter seems most likely based on published research involving deconditioned older people³⁰ and exercise intolerant patients³⁷.

To the best of our knowledge, these data are amongst the first to comprehensively assess the metabolic and physiological phenotype of quiescent CD relative to age and BMI matched HV by dovetailing exercise physiology and multiparametric ^1H MRI and ^{31}P MRS approaches. Importantly, we provide evidence of peripheral muscle deconditioning in quiescent CD patients who self-report increased fatigue perception, irrespective of no differences in muscle strength, exercise fatigue, and muscle atrophy from HV. The findings revealing a lower cerebrospinal fluid volume, and lack of increase in cerebral blood flow in response to steady-state exercise in CD compared to HV, are novel and warrant further investigation in the context of heightened fatigue perception in CD. Peripheral muscle deconditioning and altered cerebral haemodynamic response to exercise may modulate fatigue perception in IBD, which cannot be explained by deficits in cardiac and muscle function or differences in body composition. These findings give credence to the notion of exercise interventional trials to improve IBD fatigue. Future research efforts should aim to assess the efficacy of exercise training and or step count intervention to target IBD fatigue.

Acknowledgements

We would like to thank the volunteers who participated in this research study and acknowledge the technical support from staff at the David Greenfield Human Physiology Unit (DGHPU), and the Sir Peter Mansfield Imaging Centre (SPMIC) at the University of Nottingham, UK.

References

1. Edwards RH. Human muscle function and fatigue. Ciba Foundation Symposium 82- Human Muscle Fatigue: Physiological Mechanisms 1981:1-18.
2. Enoka RM, Duchateau J. Translating fatigue to human performance. *Medicine and Science in Sports and Exercise* 2016;**48**:2228-38.
3. Artom M, Czuber-Dochan W, Sturt J, Norton C. Targets for health interventions for inflammatory bowel disease-fatigue. *Journal of Crohn's and Colitis* 2016;**10**:860-9.
4. Graff LA, Clara I, Walker JR, *et al.* Changes in fatigue over 2 years are associated with activity of inflammatory bowel disease and psychological factors. *Clinical Gastroenterology and Hepatology* 2013;**11**:1140-6.
5. Van Langenberg DR, Gibson PR. Systematic review: Fatigue in inflammatory bowel disease. *Alimentary Pharmacology and Therapeutics* 2010;**32**:131-43.
6. Minderhoud IM, Samsom M, Oldenburg B. Crohn ' s disease , fatigue , and infliximab : Is there a role for cytokines in the pathogenesis of fatigue? 2007;**13**:2089-93.
7. Borren NZ, Tan W, Colizzo FP, *et al.* Longitudinal trajectory of fatigue with initiation of biologic therapy in inflammatory bowel diseases: A prospective cohort study. *Journal of Crohn's and Colitis* 2020;**14**:309-15.
8. Jelsness-Jørgensen L-P, Bernklev T, Henriksen M, Torp R, Moum BA. Chronic fatigue is more prevalent in patients with inflammatory bowel disease than in healthy controls. *Inflammatory Bowel Diseases* 2011;**17**:1564-72.
9. Farrell D, McCarthy G, Savage E. Self-reported symptom burden in individuals with inflammatory bowel disease. *Journal of Crohn's and Colitis* 2016;**10**:315-22.

10. Lönnfors S, Vermeire S, Greco M, *et al.* Ibd and health-related quality of life - discovering the true impact. *Journal of Crohn's and Colitis* 2014;**8**:1281-6.
11. Hart AL, Lomer M, Verjee A, *et al.* What are the top 10 research questions in the treatment of inflammatory bowel disease ? A priority setting partnership with the james lind alliance. 2017:204-11.
12. McGing JJ, Radford SJ, Francis ST, *et al.* The aetiology of fatigue in inflammatory bowel disease and potential therapeutic management strategies. *Alimentary Pharmacology & Therapeutics* 2021;**54**:368-87.
13. Edwards RH. Hypotheses of peripheral and central mechanisms underlying occupational muscle pain and injury. *Eur J Appl Physiol Occup Physiol* 1988;**57**:275-81.
14. Salacinski AJ, Regueiro MD, Broeder CE, McCrory JL. Decreased neuromuscular function in crohn's disease patients is not associated with low serum vitamin d levels. *Digestive Diseases and Sciences* 2013;**58**:526-33.
15. Vogelaar L, van den Berg-Emons R, Bussmann H, *et al.* Physical fitness and physical activity in fatigued and non-fatigued inflammatory bowel disease patients. *Scandinavian journal of gastroenterology* 2015;**50**:1357-67.
16. Brevinge H, Berglund B, Bosaeus I, *et al.* Exercise capacity in patients undergoing proctocolectomy and small bowel resection for Crohn's disease. *British journal of surgery*.1995;**82**:1040-5.
17. Otto JM, O'Doherty AF, Hennis PJ, *et al.* Preoperative exercise capacity in adult inflammatory bowel disease sufferers, determined by cardiopulmonary exercise testing. *International Journal of Colorectal Disease* 2012;**27**:1485-91.

18. Sarli B, Dogan Y, Poyrazoglu O, *et al.* Heart rate recovery is impaired in patients with inflammatory bowel diseases. *Medical Principles and Practice* 2016;**25**:363-7.
19. Zaltman C, Braulio VB, Outeiral R, Nunes T, Natividade de Castro CL. Lower extremity mobility limitation and impaired muscle function in women with ulcerative colitis. *Journal of Crohn's and Colitis* 2014;**8**:529-35.
20. McKeough ZJ, Alison JA, Bye PT, *et al.* Exercise capacity and quadriceps muscle metabolism following training in subjects with copd. *Respiratory medicine* 2006;**100**:1817-25.
21. Smets EMA, Garssen B, Cull A, *et al.* Application of the multidimensional fatigue inventory (MFI-20) in cancer patients receiving radiotherapy. *British journal of cancer* 1996;**73**:241-245.
22. Smets EMA, Garssen B, Bonke BD, *et al.* The Multidimensional Fatigue Inventory (MFI) Psychometric Qualities of an Instrument to Assess Fatigue. *Journal of psychosomatic research* 1995;**39**:315-325.
23. Beck A, Bager P, Jensen PE, Dahlerup JF. How fatigue is experienced and handled by female outpatients with inflammatory bowel disease. *Gastroenterology Research and Practice* 2013:1-8.
24. Mallinson JE, Marimuthu K, Murton A, *et al.* Statin myalgia is not associated with reduced muscle strength, mass or protein turnover in older male volunteers, but is allied with a slowing of time to peak power output, insulin resistance and differential muscle mrna expression. *The Journal of physiology* 2015;**593**:1239-57.

25. Gallen I, Macdonald I. Effect of two methods of hand heating on body temperature, forearm blood flow, and deep venous oxygen saturation. *American Journal of Physiology-Endocrinology and Metabolism* 1990;**259**:E639-E43.
26. Lu H, Ge Y. Quantitative evaluation of oxygenation in venous vessels using t2-relaxation-under-spin-tagging mri. *Magnetic Resonance in Medicine* 2008;**60**:357-63.
27. Kemp GJ, Ahmad RE, Nicolay K, Prompers JJ. Quantification of skeletal muscle mitochondrial function by 31p magnetic resonance spectroscopy techniques: A quantitative review. *Acta Physiologica* 2015;**213**:107-44.
28. Stefan D, Di Cesare F, Andrasescu A, *et al.* Quantitation of magnetic resonance spectroscopy signals: The jmrui software package. *Measurement Science and Technology* 2009;**20**:104035.
29. Chati Z, Zannad F, Jeandel C, *et al.* Physical deconditioning may be a mechanism for the skeletal muscle energy phosphate metabolism abnormalities in chronic heart failure. *American heart journal* 1996;**131**:560-6.
30. Broskey NT, Greggio C, Boss A, *et al.* Skeletal muscle mitochondria in the elderly: Effects of physical fitness and exercise training. *The Journal of Clinical Endocrinology & Metabolism* 2014;**99**:1852-61.
31. Gonzalez- Freire M, Adelnia F, Moaddel R, Ferrucci L. Searching for a mitochondrial root to the decline in muscle function with ageing. Wiley Online Library, 2018: 435-40.
32. Short KR, Bigelow ML, Kahl J, *et al.* Decline in skeletal muscle mitochondrial function with aging in humans. *Proceedings of the National Academy of Sciences of the United States of America* 2005;**102**:5618-23.

33. Calik-Kutukcu E, Savci S, Saglam M, *et al.* A comparison of muscle strength and endurance, exercise capacity, fatigue perception and quality of life in patients with chronic obstructive pulmonary disease and healthy subjects: A cross-sectional study. *BMC pulmonary medicine* 2014;**14**:1-10.
34. Gosker H, Hesselink M, Duimel H, Ward K, Schols A. Reduced mitochondrial density in the vastus lateralis muscle of patients with copd. *European Respiratory Journal* 2007;**30**:73-9.
35. Kutsuzawa T, Shioya S, Kurita D, *et al.* Muscle energy metabolism and nutritional status in patients with chronic obstructive pulmonary disease. A 31P magnetic resonance study. *American journal of respiratory and critical care medicine* 1995;**152**:647-52.
36. Vorrink SN, Kort HS, Troosters T, Lammers J-WJ. Level of daily physical activity in individuals with copd compared with healthy controls. *Respiratory research* 2011;**12**:1-8.
37. Latimer LE, Constantin-Teodosiu D, Popat B, *et al.* Whole-body and muscle responses to aerobic exercise training and withdrawal in ageing and copd. *European Respiratory Journal* 2022;**59**.
38. Van Langenberg DR, Della Gatta P, Warmington SA, *et al.* Objectively measured muscle fatigue in crohn's disease: Correlation with self-reported fatigue and associated factors for clinical application. *Journal of Crohn's and Colitis* 2014;**8**:137-46.
39. Tudor-Locke C, Craig CL, Thyfault JP, Spence JC. A step-defined sedentary lifestyle index:< 5000 steps/day. *Applied physiology, nutrition, and metabolism* 2013;**38**:100-14.
40. Garber CE, Blissmer B, Deschenes MR, *et al.* Quantity and quality of exercise for developing and maintaining cardiorespiratory, musculoskeletal, and neuromotor fitness in apparently healthy adults: Guidance for prescribing exercise. 2011.

41. Werkstetter KJ, Ullrich J, Schatz SB, *et al.* Lean body mass, physical activity and quality of life in paediatric patients with inflammatory bowel disease and in healthy controls. *Journal of Crohn's and Colitis* 2012;**6**:665-73.
42. Van Langenberg DR, Gatta PD, Hill B, *et al.* Delving into disability in crohn's disease: Dysregulation of molecular pathways may explain skeletal muscle loss in crohn's disease. *Journal of Crohn's and Colitis* 2014;**8**:626-34.
43. Van Langenberg DR, Papandony MC, Gibson PR. Sleep and physical activity measured by accelerometry in crohn's disease. *Alimentary Pharmacology and Therapeutics* 2015;**41**:991-1004.
44. Bilet L, Phielix E, van de Weijer T, *et al.* One-leg inactivity induces a reduction in mitochondrial oxidative capacity, intramyocellular lipid accumulation and reduced insulin signalling upon lipid infusion: A human study with unilateral limb suspension. *Diabetologia* 2020;**63**:1211-22.
45. Grevendonk L, Connell NJ, McCrum C, *et al.* Impact of aging and exercise on skeletal muscle mitochondrial capacity, energy metabolism, and physical function. *Nature communications* 2021;**12**:4773.
46. Wiroth J-B, Filippi J, Schneider SM, *et al.* Muscle performance in patients with crohn's disease in clinical remission. *Inflammatory Bowel Diseases* 2005;**11**:296-303.
47. Geerling BJ, Badart-Smook A, Stockbrugger RW, Brummer RJ. Comprehensive nutritional status in recently diagnosed patients with inflammatory bowel disease compared with population controls. *European journal of clinical nutrition* 2000;**54**:514-21.
48. Barnes WS. The relationship between maximum isometric strength and intramuscular circulatory occlusion. *Ergonomics* 1980;**23**:351-7.

49. Sejersted O, Hargens AR, Kardel KR, *et al.* Intramuscular fluid pressure during isometric contraction of human skeletal muscle. *Journal of Applied Physiology* 1984;**56**:287-95.
50. Tesch P, Thorsson A, Fujitsuka N. Creatine phosphate in fiber types of skeletal muscle before and after exhaustive exercise. *Journal of Applied Physiology* 1989;**66**:1756-9.
51. Fisher JP, Hartwich D, Seifert T, *et al.* Cerebral perfusion, oxygenation and metabolism during exercise in young and elderly individuals. *The Journal of physiology* 2013;**591**:1859-70.
52. Olesen J. Contralateral focal increase of cerebral blood flow in man during arm work. *Brain* 1971;**94**:635-46.
53. Thapaliya G, Eldeghaidy S, Asghar M, *et al.* The relationship between central nervous system morphometry changes and key symptoms in crohn's disease. *Brain Imaging and Behavior* 2023;**17**:149-60.
54. Stoquart-ElSankari S, Balédent O, Gondry-Jouet C, *et al.* Aging effects on cerebral blood and cerebrospinal fluid flows. *Journal of Cerebral Blood Flow & Metabolism* 2007;**27**:1563-72.
55. Bao D, Zhou J, Hao Y, *et al.* The effects of fatiguing aerobic exercise on the cerebral blood flow and oxygen extraction in the brain: A piloting neuroimaging study. *Frontiers in Neurology* 2019;**10**:654.
56. Van Erp S, Ercan E, Breedveld P, *et al.* Cerebral magnetic resonance imaging in quiescent crohn's disease patients with fatigue. *World Journal of Gastroenterology* 2017;**23**:1018-29.

Figure Legends

Figure 1. CONSORT diagram detailing volunteer recruitment and progression through the study protocol.

Figure 2. Post exercise PCr resynthesis after ischaemic contraction. A.) Example stacked ^{31}P metabolite plot across the exercise task from one volunteer. B.) Mean post-exercise PCr recovery curves as a function of time in 13 CD vs 9 HV. Data presented as Mean \pm SEM. Error bars are plotted in opposite directions to aid data visualization* = $P < 0.05$.

Figure 3. Central vascular and metabolic responses across sustained low-intensity exercise in HV versus CD. A.) Aortic cardiac index (7 CD, 10 HV). B.) Grey matter corrected cerebral blood flow (gmCBF; 11 CD, 8 HV). C.) Oxygen extraction fraction (OEF; n 8 HV, 10 CD). D.) Grey matter corrected cerebral metabolic rate of oxygen (gmCMRO₂; 8 HV, 10 CD). Data reported as Mean \pm SEM. * = $P < 0.05$, ** = $P < 0.01$, *** = $P < 0.001$, Two-way mixed design ANOVA.

Figure 4 A.) DEXA estimated regional and whole-body composition. B.) Peak isometric thigh strength C.) Peak isokinetic work across a series of 20 knee extension repetitions. All data presented for 11 CD and 14 HV as mean \pm SEM.

Tables

	CD (n=16, 7 female)	HV (n=12, 9 female)	<i>P</i> – value
Age (Years)	42 ± 4	38 ± 4	0.60
BMI (kg/m ²)	24.8 ± 1	24.0 ± 0.9	0.57
Daily Step count	5482 ± 684	8168 ± 1123	0.04*
Fatigue assessment			
MFI – General (0-20)	13.9 ± 1	8.3 ± 0.9	0.001*
MFI – Physical (0-20)	11.3 ± 1.2	8.4 ± 0.9	0.09
IBDF S1	8.7 ± 1.4	N/A	N/A
IBDF S2	31.5 ± 5.1	N/A	N/A
Mental health, Quality of life & Cognitive function			
HADS (0-21)	10.1 ± 1.4	7.5 ± 1.4	0.22
CUCQ-32	1.99 ± 0.23	N/A	N/A
MoCA (0-30)	26.4 ± 0.6	25.5 ± 0.8	0.36
Inflammatory markers			
TNF-alpha (pg/mL)	21.67 ± 8.83	8.12 ± 2.62	0.11
IL-1 (pg/mL)	0.39 ± 0.09	0.39 ± 0.13	0.63
IL-6 (pg/mL)	0.80 ± 0.19	0.21 ± 0.07	0.02*
CRP (mg/L)	<10	<10	N/A

Table 1. Demographic data, fatigue perception measurements, anxiety and depression symptoms, cognitive function assessment. Unpaired *t* test; mean ± SEM. **P*<0.05.

	CD	HV	P - value
DEXA Body composition (11HV, 14CD)			
Whole body lean mass	48.1 ± 2.3	47.8 ± 3.2	0.65
Lean mass index	15.8 ± 0.5	16.3 ± 0.8	0.65
Appendicular lean mass index	7.1 ± 0.3	7.2 ± 0.4	0.86
BMD	1.2	1.2	0.52
¹H MRI Body composition (11HV, 14CD)			
Whole leg muscle volume	2432 ± 88	2428 ± 81	0.97
Whole leg intra- muscular FF	14 ± 1	12 ± 1	0.32
Muscle fatiguability (11HV, 14 CD)			
Isokinetic work output	131.9 ± 5.7	140.9 ± 5.8	0.29
Thigh fatigue index	27.6 ± 2.3	22.8 ± 2.6	0.19


Table 2. Body composition and muscle fatiguability DEXA estimated whole body lean mass (kg), lean mass index (total body lean mass /ht²) and appendicular lean mass index (appendicular lean mass/ht²). ¹H MRI measurements of whole limb and calf muscle volumes normalised to body surface area (cm³) together with % fat fractions (data presented as FWHM). Muscle fatiguability data including isokinetic work output (Nm/kg leg lean mass) and thigh fatigue index (%) during 20 maximal contractions. Unpaired *t* test; mean ± SEM. **P*<0.05.

	CD (N=13)	HV (N=9)	P - Value
Baseline Calf muscle PCr (mM / L cell water)	26.2 ± 1.3	27.7 ± 1.9	0.23
End-exercise Calf muscle PCr (mM / L cell water)	3.8 ± 0.6	5.2 ± 1.0	
End-recovery Calf muscle PCr (mM / L cell water)	25.3 ± 1.64	28.9 ± 2.11	
Base Calf muscle pH	7.20 ± 0.05	7.10 ± 0.04	0.32
End-exercise Calf muscle pH	6.49 ± 0.05	6.45 ± 0.07	
End-recovery Calf muscle pH	7.13 ± 0.07	7.19 ± 0.06	
PCr Depletion (%)	84.58 ± 2.42	81.2 ± 3.0	0.39
V _{PCr} (mM min ⁻¹)	17.2 ± 2.0	25.3 ± 2.4	0.02*

Table 3. ³¹P MRS data across ischemic exercise task including calf muscle PCr concentrations, intracellular muscle pH estimations, PCr depletion rates, ³¹P derived metabolic parameters in healthy volunteers and quiescent Crohn's Disease patients. P – Values for ³¹P metabolite data across exercise derived from group main effect during Two-Way ANOVA. PCr depletion and V_{PCr} from independent t-test.

Figures


Figure 1



Accepted

Figure 2

A.



B.





Figure 3



F

Figure 4

